SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-030757
Filing Date
2024-08-08
Accepted
2024-08-08 16:06:29
Documents
59
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1361764
2 ex31-1.htm EX-31.1 18476
3 ex31-2.htm EX-31.2 18598
4 ex32-1.htm EX-32.1 7287
5 ex32-2.htm EX-32.2 7326
  Complete submission text file 0001493152-24-030757.txt   6783737

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE lixt-20240630.xsd EX-101.SCH 46482
7 XBRL CALCULATION FILE lixt-20240630_cal.xml EX-101.CAL 32244
8 XBRL DEFINITION FILE lixt-20240630_def.xml EX-101.DEF 241903
9 XBRL LABEL FILE lixt-20240630_lab.xml EX-101.LAB 405865
10 XBRL PRESENTATION FILE lixt-20240630_pre.xml EX-101.PRE 327060
61 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1139126
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

IRS No.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39717 | Film No.: 241188225
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)